{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:13:41Z","timestamp":1790878421973,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12149-024-01928-2","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T07:01:36Z","timestamp":1713942096000},"page":"553-562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis"],"prefix":"10.1007","volume":"38","author":[{"given":"Naoto","family":"Wakabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7930-0975","authenticated-orcid":false,"given":"Shiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashige","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohsuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"1928_CR1","unstructured":"Tishler  AS,  de  Krijger RR,  Gill  A, et al.: WHO classification of tumours of the adrenal medulla and extra-adrenal paraganglia. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J. (eds) WHO Classifications of Tumours of Endocrine Organs. 4th edition IARC Press, Lyon, 2017, p. 180-89."},{"key":"1928_CR2","doi-asserted-by":"crossref","unstructured":"Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. Springer Verlag; p. 1039\u201347","DOI":"10.1007\/s00259-008-0715-3"},{"key":"1928_CR3","first-page":"155","volume":"20","author":"DM Wieland","year":"1979","unstructured":"Wieland DM, Swanson DP, Brown LE, Beierwaltes WH. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med. 1979;20:155\u20138.","journal-title":"J Nucl Med"},{"key":"1928_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12149-015-0960-z","volume":"29","author":"S Kinuya","year":"2015","unstructured":"Kinuya S, Yoshinaga K, Higuchi T, Jinguji M, Kurihara H, Kawamoto H. Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors: Guideline Drafting Committee for Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine. Ann Nucl Med. 2015;29:543\u2013552.","journal-title":"Ann Nucl Med"},{"key":"1928_CR5","doi-asserted-by":"crossref","unstructured":"Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, et al. (2019) A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Sci Rep 9","DOI":"10.1038\/s41598-019-43880-6"},{"key":"1928_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s12149-021-01699-0","volume":"36","author":"A Inaki","year":"2022","unstructured":"Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, et al. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. Ann Nucl Med. 2022;36:267\u201378.","journal-title":"Ann Nucl Med"},{"key":"1928_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1507\/endocrj.EJ14-0211","volume":"61","author":"K Yoshinaga","year":"2014","unstructured":"Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, et al. Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Endocr J. 2014;61:1171\u201380.","journal-title":"Endocr J"},{"key":"1928_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/COC.0b013e31819e2c28","volume":"33","author":"M Shilkrut","year":"2010","unstructured":"Shilkrut M, Bar-Deroma R, Bar-Sela G, Berniger A, Kuten A. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: Single center experience. Am J Clin Oncol Cancer Clin Trials. 2010;33:79\u201382.","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"1928_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00259-009-1326-3","volume":"37","author":"S Navalkissoor","year":"2010","unstructured":"Navalkissoor S, Alhashimi DM, Quigley AM, Caplin ME, Buscombe JR. Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37:904\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1928_CR10","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131i]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162\u20138.","journal-title":"J Clin Oncol"},{"key":"1928_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60:623\u201330.","journal-title":"J Nucl Med"},{"key":"1928_CR12","doi-asserted-by":"crossref","unstructured":"Van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EPM (2014) 131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: Systematic review and meta-analysis. Clin Endocrinol (Oxf). Blackwell Publishing Ltd., p. 487\u2013501","DOI":"10.1111\/cen.12341"},{"key":"1928_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2967\/jnumed.120.250803","volume":"62","author":"K Yoshinaga","year":"2021","unstructured":"Yoshinaga K, Abe T, Okamoto S, Uchiyama Y, Manabe O, Ito YM, et al. Effects of Repeated 131I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors. J Nucl Med. 2021;62:685\u201394.","journal-title":"J Nucl Med"},{"key":"1928_CR14","doi-asserted-by":"crossref","unstructured":"Takenaka J, Watanabe S, Abe T, Tsuchikawa T, Takeuchi S, Hirata K, et al. (2023) Predictive Factors of Early 18F-Fluorodeoxyglucose-Positron Emission Tomography Response to [131I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas. Neuroendocrinology 1\u201311","DOI":"10.1159\/000534175"},{"key":"1928_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12149-022-01798-6","volume":"37","author":"J Takenaka","year":"2023","unstructured":"Takenaka J, Watanabe S, Abe T, Hirata K, Uchiyama Y, Kimura R, et al. Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL). Ann Nucl Med. 2023;37:10\u201317.","journal-title":"Ann Nucl Med"},{"key":"1928_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1928_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s12149-013-0755-z","volume":"27","author":"H Wakabayashi","year":"2013","unstructured":"Wakabayashi H, Taki J, Inaki A, Nakamura A, Kayano D, Fukuoka M, et al. Prognostic values of initial responses to low-dose 131I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. Ann Nucl Med. 2013;27:839\u201346.","journal-title":"Ann Nucl Med"},{"key":"1928_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","volume":"67","author":"AP Chen","year":"2012","unstructured":"Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012;67:1025\u201339.","journal-title":"J Am Acad Dermatol"},{"key":"1928_CR19","doi-asserted-by":"crossref","unstructured":"Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, et al. Malignant pheochromocytomas and paragangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci. Blackwell Publishing Inc.; 2006. p. 465\u201390","DOI":"10.1196\/annals.1353.050"},{"key":"1928_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5603\/EP.a2018.0024","volume":"69","author":"A Kotecka-Blicharz","year":"2018","unstructured":"Kotecka-Blicharz A, Hasse-Lazar K, Handkiewicz-Junak D, Gawlik T, Pawlaczek A, Oczko-Wojciechowska M, et al. 131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study. Endokrynol Pol. 2018;69:246\u201351.","journal-title":"Endokrynol Pol"},{"key":"1928_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","volume":"35","author":"GK Gedik","year":"2008","unstructured":"Gedik GK, Hoefnagel CA, Bais E, Vald\u00e9s Olmos RA. 131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:725\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1928_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","volume":"55","author":"JJ Mukherjee","year":"2001","unstructured":"Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131i-meta-iodobenzylguanidine (131I-mIBG). Clin Endocrinol (Oxf). 2001;55:47\u201360.","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01928-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-024-01928-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01928-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T12:04:29Z","timestamp":1719835469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-024-01928-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1007\/s12149-024-01928-2","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no potential conflicts of interest related to the content of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}